Real-world use of once-weekly semaglutide in Thai patients with type 2 diabetes mellitus: A retrospective monocentric study in Bangkok
- Conditions
- Primary (change in A1C) and secondary (including change in body weight, glycemic and weight-loss target achievement) endpoints were assessed between baseline and at the last follow-up visits after semaglutide treatment.SemaglutideType 2 Diabetes MellitusReal-World DataThai patients
- Registration Number
- TCTR20211014001
- Lead Sponsor
- Theptarin Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Thai patients with T2DM who initiated semaglutide for at least 1 month between 2020 and 2021 at Theptarin Hospital, Bangkok, Thailand
Exclusion Criteria
Non-Thai ethnicity
Non-T2DM
Use semaglutide less than 1 month
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in A1C from baseline to the last visit Last visit Mean changes
- Secondary Outcome Measures
Name Time Method Proportion of patients reaching both A1C target less than 7.0% and a 5% weight loss Last visit Proportion